Measurable/Minimal Residual Disease: What Method and What Cut-Off?. [Review]

No Thumbnail Available

All Authors

Rawstron, A.

LTHT Author

Rawstron, Andy

LTHT Department

Oncology
Leeds Cancer Centre
Haematological Malignancy Diagnostic Service

Non Medic

Clinical Scientist

Publication Date

2025

Item Type

Journal Article
Review

Language

Subject

Subject Headings

Abstract

Minimal residual disease (MRD) testing has become a central response biomarker in clinical trials of time-limited treatment, with MRD-guided strategies under increasing evaluation. This article compares key technical and practical features of available MRD approaches and provides guidance on selecting the appropriate method and threshold for varied clinical applications.

Journal

Hematology - Oncology Clinics of North America

URI

https://hdl.handle.net/20.500.14838/1873

DOI

https://dx.doi.org/10.1016/j.hoc.2025.05.012

Collections

External Publications